FeesSafety
Pluang+

Phase 3 trial shows 68% recurrence risk reduction in bladder cancer with cretostimogene.

Company Fundamentals
16 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Phase 3 trial shows 68% recurrence risk reduction in bladder cancer with cretostimogene.

CG Oncology announced positive Phase 3 PIVOT-006 trial results showing cretostimogene reduces recurrence risk by 68% in intermediate-risk, high-grade Ta non-muscle invasive bladder cancer (NMIBC). The treatment showed strong safety with no severe adverse events or discontinuations. These results support a planned FDA Biologics License Application (BLA) submission in mid-2027, potentially expanding treatment options for about 50,000 patients lacking approved therapies. The company also plans to broaden its initial BLA for BCG-unresponsive NMIBC to include more patient groups, aiming to improve outcomes and reduce disease burden.

The PIVOT-006 Phase 3 trial results for bladder cancer treatment show a 68% reduction in recurrence risk, highlighting a significant medical advancement. For readers following the health sector, here is Pluang's market snapshot as of Nov 16, 2026 19:13 WIB: out of 150 priced US health stocks, 67 rose and 61 fell. Notable movers include ClearPoint Neuro Inc (CLPT) at USD 8.80 with a +3.77% change and a typical hold time of 13 days, Hims and Hers Health Inc (HIMS) at USD 19.01 down by -3.65% with a 24-day hold time, and Centene Corp (CNC) at USD 73.80 up +3.55% with a 42-day hold time.

More News

Walk assist robot market to grow 15% CAGR by 2031, driven by AI, aging population, and stroke rehab demand

Walk assist robot market to grow 15% CAGR by 2031, driven by AI, aging population, and stroke rehab demand

The global walk assist robot market is projected to grow at a 15.01% CAGR from 2024 to 2031, fueled by advances in AI, machine learning, and hybrid wearable technology. Rising stroke incidence and an aging population are increasing demand for these r...

Market News
Bullish
1 hour ago
Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

The global anti-obesity drugs market is projected to grow from USD 8.96 billion in 2026 to USD 64.96 billion by 2035, driven by a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate the market with blockbuster drugs like Mounjaro, Zepbound, and Wegov...

Bullish
1 hour ago
Sandisk announces 8-for-1 stock split effective Nov 19, focusing on flash memory prices over share count.

Sandisk announces 8-for-1 stock split effective Nov 19, focusing on flash memory prices over share count.

Sandisk will execute an 8-for-1 stock split on November 19, 2026, increasing the number of shares outstanding while reducing the price per share. Despite this split, the company emphasizes that flash memory prices remain the key factor influencing it...

Company Fundamentals
Neutral
1 hour ago
Nike faces scrutiny over cost-cutting ahead of first investor day since 2017

Nike faces scrutiny over cost-cutting ahead of first investor day since 2017

Nike is under pressure to clarify its cost-cutting plans as it prepares for its first investor day since 2017, scheduled for November 16–17. Despite efforts led by CEO Elliott Hill to turn the company around, management expects revenue to decline by ...

Market News
Bearish
1 hour ago
Jackery and Every Electric launch North America's first plug-in virtual power plant for renters in NYC.

Jackery and Every Electric launch North America's first plug-in virtual power plant for renters in NYC.

Jackery and Every Electric have partnered to create North America's first plug-and-play virtual power plant (VPP) for renters and apartment residents, starting in New York City. This innovative system uses portable power stations plugged into standar...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App